Rocket Pharmaceuticals (RCKT) Projected to Post Earnings on Thursday

Rocket Pharmaceuticals (NASDAQ:RCKT) is projected to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.42) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:00 PM ET.

Rocket Pharmaceuticals Stock Performance

Rocket Pharmaceuticals stock opened at $3.45 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.30 and a quick ratio of 7.30. The firm’s fifty day moving average price is $3.49 and its 200 day moving average price is $3.39. The company has a market capitalization of $373.36 million, a price-to-earnings ratio of -1.53 and a beta of 0.48. Rocket Pharmaceuticals has a 12-month low of $2.19 and a 12-month high of $11.09.

Insiders Place Their Bets

In other Rocket Pharmaceuticals news, General Counsel Martin Wilson sold 12,253 shares of the firm’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $3.31, for a total value of $40,557.43. Following the transaction, the general counsel owned 683,376 shares of the company’s stock, valued at $2,261,974.56. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Gaurav Shah sold 12,279 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $3.31, for a total value of $40,643.49. Following the transaction, the chief executive officer directly owned 1,052,045 shares of the company’s stock, valued at $3,482,268.95. This trade represents a 1.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 28,258 shares of company stock worth $93,534 over the last three months. 24.76% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RCKT. Prudential Financial Inc. acquired a new stake in shares of Rocket Pharmaceuticals in the second quarter valued at $25,000. CANADA LIFE ASSURANCE Co raised its position in Rocket Pharmaceuticals by 94.4% in the second quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 5,926 shares in the last quarter. Franklin Resources Inc. acquired a new stake in Rocket Pharmaceuticals in the 4th quarter valued at about $38,000. Virtu Financial LLC acquired a new stake in Rocket Pharmaceuticals in the 3rd quarter valued at about $40,000. Finally, Ameriprise Financial Inc. bought a new position in shares of Rocket Pharmaceuticals during the 3rd quarter valued at about $43,000. Institutional investors and hedge funds own 98.39% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. TD Cowen upgraded Rocket Pharmaceuticals to a “hold” rating in a research note on Friday, December 19th. Bank of America cut their target price on Rocket Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. JPMorgan Chase & Co. lowered shares of Rocket Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research note on Tuesday, November 18th. Wedbush reiterated an “outperform” rating and set a $16.00 price objective on shares of Rocket Pharmaceuticals in a research note on Friday, November 7th. Finally, Morgan Stanley set a $5.00 target price on shares of Rocket Pharmaceuticals in a research report on Thursday, January 8th. Eight analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $14.36.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.